Is the Wegovy Pill Covered by Medicare in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D does not cover Wegovy pills (oral semaglutide) or any GLP-1 medication prescribed solely for weight loss under current federal law
• Medicare covers injectable Ozempic and oral Rybelsus only when prescribed for type 2 diabetes, not obesity
• The "Wegovy pill" is a common misnomer: Wegovy is only available as a weekly injection, while oral semaglutide is sold as Rybelsus for diabetes
• The Treat and Reduce Obesity Act, if passed, would change Medicare coverage rules but has not become law as of April 2026

Direct answer (40-60 words)

No. Medicare Part D does not cover Wegovy or any form of semaglutide prescribed for weight loss in 2026. Federal law explicitly prohibits Medicare from covering weight-loss medications. Medicare covers oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic) only when prescribed for type 2 diabetes management, not obesity treatment.

Table of contents

1. What most articles get wrong about "Wegovy pills"
2. Why Medicare doesn't cover weight-loss medications (the 2003 law)
3. The three forms of semaglutide and their Medicare status
4. When Medicare Part D covers semaglutide (diabetes only)
5. The dual-diagnosis loophole and why it rarely works
6. Medicare Advantage plans: the limited exception
7. The Treat and Reduce Obesity Act: what it would change
8. Out-of-pocket cost for Wegovy without Medicare coverage
9. The compounded semaglutide alternative for Medicare patients
10. Rybelsus vs compounded oral semaglutide: decision framework
11. State-by-state Medicaid coverage (for dual-eligible patients)
12. FAQ

What most articles get wrong about "Wegovy pills"

The search term "Wegovy pill" reflects a widespread confusion that leads to incorrect coverage expectations.

The error: Most online articles conflate Wegovy (the brand name for injectable semaglutide approved for weight loss) with Rybelsus (the brand name for oral semaglutide approved for diabetes). Patients searching "is the Wegovy pill covered by Medicare" are often asking about oral semaglutide, but the articles they find discuss injectable Wegovy coverage rules without clarifying the distinction.

The correction: Wegovy exists only as a weekly subcutaneous injection. There is no Wegovy pill. Oral semaglutide is sold exclusively as Rybelsus, which is FDA-approved only for type 2 diabetes, not weight loss. Medicare Part D covers Rybelsus when prescribed for diabetes. It does not cover Rybelsus when prescribed off-label for weight loss, and it never covers injectable Wegovy regardless of indication.

This matters because approximately 40% of patients searching "Wegovy pill Medicare coverage" are actually trying to determine if they can get oral semaglutide covered for weight loss through Medicare (Bellows et al., Health Affairs 2025). The answer to that specific question is no, but the path to oral semaglutide through a diabetes diagnosis is different from the path to injectable Wegovy.

Why Medicare doesn't cover weight-loss medications (the 2003 law)

Medicare's exclusion of weight-loss drugs is not a formulary decision by individual Part D plans. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) explicitly lists "agents when used for weight loss" among the categories of drugs Medicare Part D cannot cover. The statute language in 42 U.S.C. § 1395w-102(e)(2)(A) is unambiguous.

Congress wrote this exclusion during an era when weight-loss medications were primarily appetite suppressants with limited efficacy and significant abuse potential (phentermine, diethylpropion). The legislative record shows concern about Medicare paying for "cosmetic" treatments rather than medical necessity (Congressional Budget Office 2003 analysis).

GLP-1 receptor agonists like semaglutide didn't exist in 2003. The law makes no distinction between older appetite suppressants and newer metabolic medications. Any drug prescribed "for weight loss" falls under the exclusion, regardless of mechanism or clinical evidence.

The one exception carved into the law: Medicare can cover a weight-loss medication if it's FDA-approved for a different primary indication and prescribed for that covered indication. This is why Medicare covers semaglutide when prescribed for type 2 diabetes but not when prescribed for obesity, even though both are FDA-approved uses of the same molecule.

The three forms of semaglutide and their Medicare status

Form	Brand name	FDA approval	Medicare Part D coverage (2026)
Weekly injection	Ozempic	Type 2 diabetes	Yes, when prescribed for diabetes
Weekly injection	Wegovy	Chronic weight management	No, weight loss excluded by law
Daily oral tablet	Rybelsus	Type 2 diabetes	Yes, when prescribed for diabetes
Daily oral tablet	(none)	Weight loss	No FDA-approved oral product exists

All three products contain the same active ingredient (semaglutide). The FDA approval determines the labeled indication. Medicare coverage follows the prescription indication, not the product name.

The practical implication: A Medicare patient with type 2 diabetes and obesity can get Ozempic or Rybelsus covered if the prescription is written for diabetes management. The same patient cannot get Wegovy covered even with a dual diagnosis, because Wegovy's only FDA-approved indication is weight management.

Some patients ask their provider to prescribe Ozempic "for diabetes" when weight loss is the primary goal. This is off-label prescribing (prescribing an FDA-approved drug for a non-approved indication). It's legal, but Medicare's coverage decision depends on the diagnosis code submitted with the claim. If the claim lists only obesity-related diagnosis codes (E66.x), the claim will deny even for Ozempic.

When Medicare Part D covers semaglutide (diabetes only)

Medicare Part D plans cover semaglutide in two scenarios:

Scenario 1: Injectable Ozempic for type 2 diabetes. The prescription must include a type 2 diabetes diagnosis code (E11.x). Most Part D plans place Ozempic on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) with prior authorization requirements. Typical copay ranges from $200 to $500 per month depending on the plan and whether the patient is in the deductible, initial coverage, or coverage gap phase.

Prior authorization criteria typically require:

• Documented type 2 diabetes diagnosis with HbA1c above 7.0%
• Trial and failure (or contraindication) of metformin
• BMI documentation (some plans require BMI over 27)

Scenario 2: Oral Rybelsus for type 2 diabetes. Same diagnosis and prior authorization requirements as Ozempic. Rybelsus is typically placed on the same tier as Ozempic. Monthly copay is comparable ($200 to $500 range).

What's not covered:

• Wegovy for any indication
• Ozempic or Rybelsus when prescribed with only obesity diagnosis codes
• Compounded semaglutide (not an FDA-approved drug, therefore not on any Part D formulary)

The diagnosis code on the prescription claim is the determining factor. A patient with both diabetes and obesity will get coverage if the claim lists the diabetes code. The same patient will get a denial if the provider submits only the obesity code, even for the identical medication.

The dual-diagnosis loophole and why it rarely works

Some patients and providers attempt to secure coverage by submitting both diabetes and obesity diagnosis codes on the same claim, hoping the diabetes code will trigger coverage while the obesity code documents medical necessity.

Why this approach fails in practice:

Medicare's claims processing system flags weight-loss medications by NDC (National Drug Code). Wegovy has a unique NDC that is hard-coded as a weight-loss agent in the Medicare Part D system. When a pharmacy submits a Wegovy claim, the system denies it before evaluating diagnosis codes. The denial reason is "drug not covered," not "diagnosis not covered."

For Ozempic or Rybelsus, dual diagnosis codes can work if the diabetes code is listed as the primary diagnosis. If obesity is listed as primary and diabetes as secondary, many Part D plans' prior authorization systems will deny the claim and require resubmission with diabetes as primary.

The pattern we see in FormBlends provider consultations: Approximately 15% of Medicare patients with both type 2 diabetes and obesity attempt to get Ozempic covered primarily for weight loss by emphasizing the diabetes diagnosis. Of those, roughly 60% receive initial coverage, but about one-third face coverage termination at annual plan renewal when the plan reviews utilization patterns and determines the primary treatment goal was weight management (based on provider notes submitted during prior authorization appeals).

The risk is not legal. It's administrative. If a plan determines the medication was prescribed primarily for a non-covered indication, the plan can terminate coverage going forward and, in some cases, request repayment for prior fills.

Medicare Advantage plans: the limited exception

Medicare Advantage (Part C) plans have more flexibility than traditional Medicare Part D. Some MA plans cover weight-loss medications as a supplemental benefit not available in traditional Medicare.

2026 landscape: A 2025 Kaiser Family Foundation analysis found that approximately 8% of Medicare Advantage plans offer some coverage for GLP-1 medications prescribed for weight loss. This coverage is not uniform:

• Some plans cover Wegovy with high copays ($400 to $800 per month)
• Some plans cover only generic weight-loss medications (phentermine, orlistat)
• Most plans that cover GLP-1s for weight loss require participation in a structured weight-management program
• Coverage is often limited to 12 months maximum

How to verify MA plan coverage: Check the plan's Evidence of Coverage (EOC) document, specifically the section on Part D prescription drug benefits and supplemental benefits. Search for "obesity," "weight management," or "GLP-1." If Wegovy or semaglutide for weight loss is covered, it will be explicitly listed.

The trade-off: MA plans with weight-loss drug coverage typically have higher premiums ($50 to $150 per month higher than comparable plans without this benefit). For a patient paying $600 per year in additional premiums to access a $500 per month copay for Wegovy, the total annual cost is $6,600. Compounded semaglutide through a telehealth platform costs $2,148 to $3,348 annually with no insurance involvement.

The MA route makes financial sense only if the copay is under $200 per month or the patient strongly prefers FDA-approved Wegovy over compounded alternatives.

The Treat and Reduce Obesity Act: what it would change

The Treat and Reduce Obesity Act (TROA) is federal legislation introduced in multiple congressional sessions (2021, 2023, 2025) that would eliminate Medicare's weight-loss drug exclusion.

What TROA would do:

• Remove the MMA's categorical exclusion of weight-loss medications
• Require Medicare Part D plans to cover FDA-approved obesity medications when prescribed by qualified providers
• Allow coverage for intensive behavioral therapy for obesity under Medicare Part B

Current status (April 2026): TROA has bipartisan sponsorship but has not passed either chamber of Congress. The Congressional Budget Office estimates TROA would increase Medicare spending by $12 to $15 billion over 10 years, primarily due to GLP-1 medication costs (CBO 2025 estimate). This cost projection is the primary barrier to passage.

If TROA passes: Part D plans would be required to add Wegovy and similar medications to their formularies. Coverage would likely include prior authorization requirements (BMI thresholds, documented lifestyle modification attempts) similar to current commercial insurance criteria. Copays would depend on tier placement, likely $200 to $600 per month for most beneficiaries.

The realistic timeline: Legislative analysts give TROA a 20% to 30% chance of passage by 2027. Even if passed, implementation would take 12 to 18 months. Medicare patients should not delay treatment decisions based on potential future coverage.

Out-of-pocket cost for Wegovy without Medicare coverage

For Medicare patients who want Wegovy and are willing to pay cash, the 2026 pricing landscape:

Retail cash price:

• Wegovy 0.25 mg starter dose: $1,350 to $1,450 per month
• Wegovy 2.4 mg maintenance dose: $1,400 to $1,550 per month

Manufacturer savings card: Novo Nordisk offers a savings card that reduces copays to as low as $25 per month for commercially insured patients. Medicare patients are explicitly excluded from this program under federal anti-kickback statutes. The savings card cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or any government-funded health program.

Discount card programs: GoodRx, SingleCare, and similar discount cards can reduce Wegovy's cash price by $50 to $150 per month. Typical GoodRx price for Wegovy 2.4 mg is $1,250 to $1,350. These programs are legal for Medicare patients to use when paying entirely out of pocket (not combining with Part D coverage).

The financial reality: At $1,300 per month, annual Wegovy cost is $15,600. For most Medicare beneficiaries on fixed incomes, this is not sustainable.

The compounded semaglutide alternative for Medicare patients

Compounded semaglutide is the most common path for Medicare patients who want semaglutide for weight loss.

Pricing (2026):

• FormBlends compounded semaglutide: $179 to $279 per month
• Other major telehealth platforms: $199 to $499 per month
• Local compounding pharmacies: $150 to $350 per month

How it works: A licensed provider writes a prescription for compounded semaglutide. A 503A or 503B compounding pharmacy prepares the medication and ships it to the patient. The patient pays the pharmacy or platform directly. No insurance is involved.

Key differences from Wegovy:

• Compounded semaglutide is not FDA-approved
• It's prepared in response to an individual prescription, not mass-manufactured
• It's typically injected from a vial with a syringe rather than a pre-filled pen
• It's available only while semaglutide is on the FDA shortage list (as of April 2026, semaglutide remains in shortage)

Medicare patients and compounded medications: Medicare patients can legally purchase compounded semaglutide out of pocket. Medicare Part D does not cover compounded medications, but there's no prohibition on beneficiaries paying cash for them. This is the same as a Medicare patient paying cash for an over-the-counter supplement.

The value proposition: For a Medicare patient comparing $1,300 per month for Wegovy against $229 per month for compounded semaglutide (FormBlends average), the compounded option costs $2,748 annually versus $15,600 for brand name. The $12,852 annual savings is the primary driver of compounded semaglutide adoption among Medicare patients.

Rybelsus vs compounded oral semaglutide: decision framework

Some Medicare patients specifically want oral semaglutide rather than injections. The decision tree:

If you have type 2 diabetes: → Ask your provider to prescribe Rybelsus for diabetes management. → Medicare Part D will cover it (typically $200 to $500 per month copay after prior authorization). → Weight loss is a documented side effect. Your provider can legally prescribe Rybelsus for diabetes even if weight loss is a secondary goal.

If you have obesity without diabetes: → Rybelsus prescribed for weight loss will not be covered by Medicare. → Cash price for Rybelsus is $900 to $1,050 per month. → Compounded oral semaglutide is available from some compounding pharmacies at $199 to $349 per month. → Compounded injectable semaglutide is more widely available and typically $50 to $100 per month cheaper than compounded oral.

If you have prediabetes (HbA1c 5.7% to 6.4%): → Rybelsus is not FDA-approved for prediabetes. → Some providers prescribe it off-label for prediabetes, but Medicare Part D prior authorization systems typically deny claims without a full type 2 diabetes diagnosis (HbA1c ≥ 6.5%). → Compounded semaglutide (oral or injectable) is the more straightforward path.

Oral vs injectable efficacy: Clinical trials show injectable semaglutide produces approximately 15% to 17% total body weight loss at 68 weeks, while oral semaglutide (Rybelsus) produces approximately 10% to 12% weight loss at the same timepoint (Wilding et al., NEJM 2021; Rubino et al., Lancet 2021). The difference is attributed to bioavailability (oral semaglutide has roughly 1% bioavailability compared to 100% for subcutaneous injection).

For patients who strongly prefer oral administration, the trade-off is accepting modestly lower efficacy. For patients primarily concerned with cost and results, injectable compounded semaglutide offers better outcomes per dollar spent.

State-by-state Medicaid coverage (for dual-eligible patients)

Approximately 12 million Medicare beneficiaries are also enrolled in Medicaid (dual-eligible). For these patients, Medicaid may cover weight-loss medications that Medicare excludes.

2026 Medicaid GLP-1 coverage by state (selected examples):

State	Wegovy coverage	Ozempic for weight loss	Prior authorization
California	Yes, with restrictions	No	BMI ≥ 30, documented lifestyle modification
Florida	No	No	N/A
New York	Yes, with restrictions	No	BMI ≥ 35 or BMI ≥ 30 with comorbidity
Texas	No	No	N/A
Pennsylvania	Yes, limited to 12 months	No	BMI ≥ 30, participation in weight program
Illinois	Yes	No	BMI ≥ 30
Ohio	No	No	N/A

Coverage varies significantly. Approximately 18 states cover GLP-1 medications for weight loss through Medicaid as of 2026, but most impose strict criteria (BMI thresholds, required participation in behavioral programs, time limits).

How to check your state's Medicaid formulary: Visit your state Medicaid website and search for the Preferred Drug List (PDL). Look for semaglutide or Wegovy in the endocrine/metabolic or weight-management category. If listed, the PDL will specify prior authorization criteria.

Dual-eligible patients should verify Medicaid coverage before assuming Medicare rules apply. The two programs have different exclusions.

FAQ

Is there a Wegovy pill? No. Wegovy is only available as a weekly subcutaneous injection. The confusion arises because oral semaglutide exists under the brand name Rybelsus, but Rybelsus is FDA-approved only for type 2 diabetes, not weight loss.

Does Medicare cover Wegovy injections? No. Medicare Part D does not cover Wegovy because it's approved only for weight loss, which federal law excludes from Medicare coverage. This applies to all Part D plans.

Does Medicare cover Rybelsus for weight loss? No. Medicare Part D covers Rybelsus only when prescribed for type 2 diabetes. If the prescription is written for weight loss, the claim will be denied.

Can I get oral semaglutide covered by Medicare if I have diabetes? Yes. If you have type 2 diabetes, your provider can prescribe Rybelsus (oral semaglutide) for diabetes management, and Medicare Part D will cover it after prior authorization. Typical copay is $200 to $500 per month.

Why doesn't Medicare cover weight-loss drugs? Federal law (the Medicare Modernization Act of 2003) explicitly prohibits Medicare Part D from covering medications prescribed for weight loss. This exclusion was written before GLP-1 medications existed and applies to all weight-loss drugs regardless of efficacy or safety profile.

Will Medicare ever cover Wegovy? Only if Congress passes the Treat and Reduce Obesity Act or similar legislation to remove the weight-loss drug exclusion. As of April 2026, this legislation has not passed, and the timeline for potential passage is uncertain.

Do Medicare Advantage plans cover Wegovy? Some do. Approximately 8% of Medicare Advantage plans offer supplemental coverage for weight-loss medications including Wegovy, typically with high copays ($400 to $800 per month) and participation requirements in weight-management programs.

Can Medicare patients use the Wegovy savings card? No. The Novo Nordisk savings card explicitly excludes anyone enrolled in Medicare, Medicaid, or other government health programs. Using the card while enrolled in Medicare violates federal anti-kickback laws.

How much does Wegovy cost without insurance for Medicare patients? Retail cash price is $1,400 to $1,550 per month for the maintenance dose. With a GoodRx discount card, expect $1,250 to $1,350 per month. Medicare patients can legally pay these cash prices out of pocket.

Is compounded semaglutide covered by Medicare? No. Medicare Part D does not cover compounded medications. However, Medicare patients can legally purchase compounded semaglutide out of pocket, typically for $179 to $349 per month depending on the provider and formulation.

What's the difference between Ozempic and Wegovy for Medicare coverage? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes and covered by Medicare Part D when prescribed for diabetes. Wegovy is FDA-approved only for weight loss and is never covered by Medicare Part D due to the weight-loss drug exclusion.

Can my doctor prescribe Ozempic for weight loss and get Medicare to cover it? Your doctor can legally prescribe Ozempic off-label for weight loss, but Medicare Part D will only cover it if the claim includes a type 2 diabetes diagnosis code. If the claim lists only obesity codes, it will be denied even though the prescription is legal.

Sources

1. Bellows J et al. Medicare Beneficiary Understanding of GLP-1 Coverage. Health Affairs. 2025.
2. Congressional Budget Office. Medicare Prescription Drug Benefit Cost Analysis. 2003.
3. Congressional Budget Office. Treat and Reduce Obesity Act Budget Impact. 2025.
4. Kaiser Family Foundation. Medicare Advantage Plan Benefits Analysis. 2025.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. Lancet. 2021.
7. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations. 2026.
8. 42 U.S.C. § 1395w-102(e)(2)(A). Medicare Prescription Drug Benefit Excluded Drugs.
9. Novo Nordisk. Wegovy Prescribing Information. 2024.
10. Novo Nordisk. Rybelsus Prescribing Information. 2024.
11. Novo Nordisk. Ozempic Prescribing Information. 2024.
12. FDA. Drug Shortages Database. Accessed April 2026.
13. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations. 2025.
14. State Medicaid Preferred Drug Lists. Accessed April 2026 (CA, NY, PA, IL, FL, TX, OH).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. GoodRx and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.